Wes Trotter

Wes Trotter, Ph.D.

Senior Vice President, Drug Discovery & Pharmaceutical Development

Dr. Wes Trotter, Ph.D., joined Kronos Bio in January 2020 and serves as Senior Vice President, Drug Discovery and Pharmaceutical Development. In this role he has primary responsibility for the discovery chemistry, in vitro pharmacology, and pharmaceutical development functions that drive screening, molecular optimization, and IND-enabling studies to produce Kronos Bio’s development candidates.

Before his tenure at Kronos Bio, Wes spent more than 20 years at Merck & Co. in roles of increasing responsibility in drug discovery at both the West Point, Pennsylvania and Boston, Massachusetts sites. Wes and his teams discovered and advanced into clinical development molecules addressing challenging oncology, immunology, cardiovascular, and neuroscience targets.

Wes’s contributions have made a lasting impact on the oncology and immunology treatment landscape. Preclinical and clinical candidate molecules invented by Wes and his teams for oncology and immunology indications include orally dosed protein-protein interaction inhibitors, inhaled kinase inhibitors, nuclear hormone receptor antagonists, and intratumorally administered innate immune agonists.

Wes earned his Ph.D. in synthetic organic chemistry at Harvard University under the direction of David Evans. He completed an M. Phil. in bio-organic chemistry at the University of Cambridge in the laboratory of Dudley Williams and received a B.S. in Chemistry from the University of North Carolina at Chapel Hill. As our SVP, Drug Discovery and Pharmaceutical Development, Wes’s leadership and scientific acumen are instrumental in advancing Kronos Bio’s discovery and development of therapeutics for cancer and other serious diseases.